Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare maternal and neonatal outcomes of pregestational and gestational diabetics treated with insulin glargine versus Neutral Protamine Hagedorn (NPH) insulin. METHODS: A retrospective cohort study examining outcomes from pregestational and gestational diabetics treated with either insulin regimen. Comparisons were made using the t-test for continuous data and the Chi-square or Fisher's exact test for categorical data. RESULTS: Fifty-two pregnant women treated with insulin glargine were compared with 60 pregnant women treated with NPH. No significant differences in rates of maternal complications were noted. No significant differences in neonatal outcomes for gestational diabetics were noted. Among pregestational diabetics treated with insulin glargine, significantly fewer macrosomic infants (relative risk [RR], 0.38; 95% confidence intervals (CI), 0.17-0.87; p = 0.04) and lower rates of neonatal hyperbilirubinemia (RR, 0.27; 95% CI, 0.07-0.98; p = 0.05) were noted when compared with those treated with NPH. There were no cases of neonatal hypoglycemia in pregestational diabetics treated with glargine; however, 25% of infants born to mothers treated with NPH experienced hypoglycemia (p = 0.01). No fetal anomalies or deaths were observed in either treatment group. CONCLUSION: Insulin glargine use during pregnancy is not associated with increased maternal or neonatal morbidity compared with NPH insulin. Among pregestational diabetics, insulin glargine use was associated with lower rates of macrosomia, neonatal hypoglycemia and neonatal hyperbilirubinemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several retrospective cohort and case-control studies of pregnant women found that overall, the outcome with insulin glargine treatment was no different from, or was superior to, NPH insulin (35, 145–149).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [147]
In the citing paper
“Several retrospective cohort and case-control studies of pregnant women found that overall, the outcome with insulin glargine treatment was no different from, or was superior to, NPH insulin (35, 145–149).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [146]
Citations
Cites
A united states national reference for fetal growth
ALEXANDER, G., HIMES, J., KAUFMAN, R., MOR, J., & KOGAN, M. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(95)00386-x · Cited by 2,294
Criteria for screening tests for gestational diabetes
Carpenter, M. W., & Coustan, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90349-0 · Cited by 1,924
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 1×
“A concern regarding the use of insulin glargine in pregnancy is because of its potential to stimulate growth due to the increased affinity of insulin glargine for the insulin-like growth factor receptor [15].”
BackgroundHirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
Heinemann, L., Linkeschova, R., Rave, K., Hompesch, B., Sedlak, M., & Heise, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.644 · Cited by 473
Classification of obstetric diabetes
White, P. (1978) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(78)90373-3 · Cited by 184
Use of insulin glargine during pregnancy: a case-control pilot study
Price, N., Bartlett, C., & Gillmer, M. (2007) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.01216.x · Cited by 93
Hofmann, T., Horstmann, G., & Stammberger, I. (2002) · International Journal of Toxicology · doi:10.1080/10915810290096315 · Cited by 77
Barnett, A. H. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00996.x · Cited by 61
Cited by
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
Safety of insulin analogs during pregnancy: a meta-analysis
Lv, S., Wang, J., & Xu, Y. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3692-3 · Cited by 88
Negrato, C. A., Rafacho, A., Negrato, G., Teixeira, M. F., Araújo, C. A. R., Vieira, L., Silva, C. A., Date, S. K., Demarchi, A. C., & Gomes, M. B. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.015 · Cited by 55
Mathiesen, E. R., Damm, P., Jovanovic, L., McCance, D. R., Thyregod, C., Jensen, A. B., & Hod, M. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1213 · Cited by 43
Insulin Glargine Use During Pregnancy
Pantalone, K. M., Faiman, C., & Olansky, L. (2011) · Endocrine Practice · doi:10.4158/ep11083.ra · Cited by 13
Metadata
- Authors
- Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M.
- Affiliations
- University of Connecticut (US)
- Saint Francis Hospital & Medical Center (US)
- Corresponding author
- Zelop, Carolyn M.
- ORCID
- Zelop, Carolyn M.
- Venue
- The Journal of Maternal-Fetal & Neonatal Medicine
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 22
- Issue
- 3
- Pages
- 249-253
- ISSN
- 1476-4954 (ISSN-L)
- 1476-7058
- OpenAlex
- W2002981359
- Cited by
- 45
- References
- 16
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 2 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 4 · 2014: 2 · 2013: 6 · 2012: 7
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Maternal-Fetal & Neonatal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin glargine, NPH insulin, gestational diabetes mellitus, pregestational diabetes, diabetes in pregnancy, neonatal outcomes, macrosomia, neonatal hypoglycemia, neonatal hyperbilirubinemia, maternal complications, insulin analogues
- MeSH terms
- Insulin Glargine, Adult, Female, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Insulin, Isophane, Male, Pregnancy, Pregnancy in Diabetics, Pregnancy Outcome, Retrospective Studies, Cohort Studies, Diabetes, Gestational, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. https://app.cochat.ai/papers/10.1080/14767050802638170
- The paper
- Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M. (2009). Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. The Journal of Maternal-Fetal & Neonatal Medicine. https://doi.org/10.1080/14767050802638170
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.